Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus intensive chemotherapy versus standard intensive chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
ACTRN12625001003460Phase 3Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Event-free survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12625001003460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001003460.